g****e
发帖数: 1426 | 1 ALXA still has huge upside in near term:
1. Today's partnership news with TEVA:
TEVA will pay Alexza $40 million upfront and it could make another $195
million in milestone payments based on completion of post-approval studies
and sales targets. Alexza will also receive royalties on sales of the drug,
and Teva will lend Alexza up to $25 million to support Adasuve activities
over the next five years.
2. Highly undervalued, market cap is only $83.78m with today's share closing
price $5.31. Total cash (mrq): 17.72m and total debt (mrq): 6.46m at the
end of last Q.
3. Recent insider buy:
Mar 28, 2013 SCHINELLER PETER W. Officer 43,750 shares at $4.42
Mar 28, 2013 CASSELLA JAMES V Officer 43,750 shares at $4.42
Mar 28, 2013 OKI MARK K Officer 43,750 shares at $4.42
Mar 28, 2013 MORELAND DARL Officer 43,750 shares at $4.42
Mar 28, 2013 KING THOMAS BRAXTON Officer 175,000 sharesat $4.42
Mar 28, 2013 SIMMS MICHAEL J Officer 43,750 shares at $4.42
4.Today's partnership deal validates the market value of ALXA's key delivery
technology Staccato® system:
'We have already demonstrated that more than 200 FDA-approved compounds are
feasible for delivery by the Staccato® system. Currently we have six
development programs focused on different acute and intermittent conditions.
'--ALXA
YMYD, good luck. | d********1
发帖数: 8969 | 2 high risk one. Is it too late to load? |
|
